What IDEAYA Biosciences’ IDE892 expansion means for MTAP-deleted cancers
IDEAYA advances IDE892 into expansion after reaching target exposure, but clinical response and safety data remain the decisive test.
Pharma & Biotech
Pharma & Biotech
A promising eye cancer drug shrank tumors in phase 1, so why did Novartis stop developing DYP688?
DYP688 showed early activity and manageable toxicity in metastatic uveal melanoma, but Novartis has halted development despite the clinical signal.
Pharma & Biotech
IDEAYA Biosciences expands ESMO 2026 catalyst slate across eye and lung cancer
IDEAYA Biosciences will use ESMO 2026 to expand the clinical case for darovasertib across three uveal melanoma settings and test the durability of IDE849 responses in small-cell lung cancer.
Pharma & Biotech
What to watch as IDEAYA Biosciences reports OptimUM-02 topline results in uveal melanoma
IDEAYA Biosciences will report OptimUM-02 topline data on April 13. Read why this uveal melanoma trial could shift the treatment landscape.
Pharma & Biotech
Could IDEAYA Biosciences challenge current standards in metastatic uveal melanoma with darovasertib?
IDEAYA Biosciences nears darovasertib trial data. Discover how results could reshape metastatic uveal melanoma treatment strategies.
Pharma & Biotech
Can IDEAYA’s darovasertib finally redefine first-line therapy in metastatic uveal melanoma?
IDEAYA Biosciences has completed targeted full enrollment in its Phase 2/3 OptimUM-02 trial evaluating darovasertib in combination with crizotinib as a first-line treatment for HLA*A2-negative metastatic uveal melanoma. The company aims to support a potential accelerated approval filing in the United States based on median progression-free survival data expected in the first quarter of 2026.
Pharma & Biotech
Can IDE574 reshape breast and lung cancer treatment by targeting KAT6 and KAT7?
IDEAYA Biosciences files IND for IDE574, a KAT6/7 inhibitor for breast and lung cancer. Learn how this new class may change epigenetic treatment strategies.